Antisense Oligonucleotides for Alpha-Synuclein Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments for neurodegenerative diseases such as Parkinson's disease, dementia, multiple system atrophy, and Alzheimer's disease, which are associated with the misfolding and aggregation of alpha-synuclein protein.
Innovation Solution
The development of methods, compounds, and compositions that specifically inhibit the expression of alpha-synuclein mRNA and protein, using alpha-synuclein specific inhibitors such as nucleic acids, proteins, antibodies, or small molecules, to reduce alpha-synuclein levels in cells and tissues, particularly in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alpha-synuclein expression is inhibited to treat neurodegenerative diseases, then disease progression is slowed, but potential off-target effects and safety issues arise
Solution Approach 1:
The patent employs antisense oligonucleotides with specific sequence complementarity to target only alpha-synuclein mRNA, ensuring localized action at the molecular level. The oligonucleotides are designed to bind specifically to the alpha-synuclein gene sequence, preventing translation only for this protein while leaving other proteins unaffected, thus resolving the contradiction between effective targeting and avoiding off-target effects.
Solution Approach 2:
The patent uses antisense oligonucleotides as intermediary molecules that mediate between the therapeutic goal (reducing alpha-synuclein) and the potential harm (off-target effects). These oligonucleotides act as precise intermediaries that can be designed to bind only to the specific mRNA sequence, serving as a controlled mechanism to reduce protein expression without affecting other cellular processes.
2Adaptability or versatility
If multiple types of inhibitors are developed to target alpha-synuclein, then treatment options increase, but complexity of the therapeutic approach increases
Solution Approach 1:
The patent segments the inhibition strategy into different classes of inhibitors (antisense oligonucleotides, small molecules, antibodies) targeting different aspects of alpha-synuclein expression or function. This segmentation allows for specialized development of each inhibitor type optimized for its specific mechanism, while the overall approach remains coordinated through a unified therapeutic strategy focused on reducing alpha-synuclein pathology.
Data Source
AI summary
Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.